Cancer-Associated Transforming Growth Factor β Type II Receptor Gene Mutant Causes Activation of Bone Morphogenic Protein-Smads and Invasive Phenotype
Authors:
Open Access
- 13 March 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (6) , 1656-1666
Abstract
Transforming growth factor β (TGFβ) plays a key role in maintaining tissue homeostasis by inducing cell cycle arrest, differentiation and apoptosis, and ensuring genomic integrity. Furthermore, TGFβ orchestrates the response to tissue injury and mediates repair by inducing epithelial to mesenchymal transition and by stimulating cell motility and invasiveness. Although loss of the homeostatic activity of TGFβ occurs early on in tumor development, many advanced cancers have coopted the tissue repair function to enhance their metastatic phenotype. How these two functions of TGFβ become uncoupled during cancer development remains poorly understood. Here, we show that, in human keratinocytes, TGFβ induces phosphorylation of Smad2 and Smad3 as well as Smad1 and Smad5 and that both pathways are dependent on the kinase activities of the type I and II TGFβ receptors (TβR). Moreover, cancer-associated missense mutations of the TβRII gene (TGFBR2) are associated with at least two different phenotypes. One type of mutant (TGFBR2E526Q) is associated with loss of kinase activity and all signaling functions. In contrast, a second mutant (TGFBR2R537P) is associated with high intrinsic kinase activity, loss of Smad2/3 activation, and constitutive activation of Smad1/5. Furthermore, this TGFBR2 mutant endows the carcinoma cells with a highly motile and invasive fibroblastoid phenotype. This activated phenotype is TβRI (Alk-5) independent and can be reversed by the action of a dual TβRI and TβRII kinase inhibitor. Thus, identification of such activated TβRII receptor mutations in tumors may have direct implications for appropriately targeting these cancers with selective therapeutic agents. [Cancer Res 2008;68(6):1656–66]Keywords
This publication has 34 references indexed in Scilit:
- Reassessing Epithelial to Mesenchymal Transition as a Prerequisite for Carcinoma Invasion and MetastasisCancer Research, 2006
- Kinetic Characterization of Novel Pyrazole TGF-β Receptor I Kinase Inhibitors and Their Blockade of the Epithelial−Mesenchymal TransitionBiochemistry, 2005
- Development of TGF-β signalling inhibitors for cancer therapyNature Reviews Drug Discovery, 2004
- TGF-β signaling: positive and negative effects on tumorigenesisCurrent Opinion in Genetics & Development, 2002
- Heterozygous inactivation of TGF-β1 increases the susceptibility to chemically induced mouse lung tumorigenesis independently of mutational activation of K-rasToxicology Letters, 2001
- Enhanced tumorigenesis and reduced transforming growth factor-? type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-?1Molecular Carcinogenesis, 2000
- Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesisCytokine & Growth Factor Reviews, 2000
- Two Divergent Signaling Pathways for TGF-β Separated by a Mutation of Its Type II Receptor GeneBiochemical and Biophysical Research Communications, 1999
- HNPCC associated with germline mutation in the TGF-β type II receptor geneNature Genetics, 1998
- TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors.Journal of Cell Biology, 1994